<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" version="2.0" nsmap="{'media': 'http://search.yahoo.com/mrss/'}"><channel><title>Raichur News Feed</title><link>https://news.google.com/rss/search?q=raichur&amp;hl=en-US&amp;gl=US&amp;ceid=US:en</link><description>Latest news about Raichur</description><language>en-US</language><item><title>Shilpa Pharma Lifesciences’ Raichur API facility clears second consecutive FDA inspection with no observations</title><link>https://www.expresspharma.in/shilpa-pharma-lifesciences-raichur-api-facility-clears-second-consecutive-fda-inspection-with-no-observations/</link><description>&lt;![CDATA[Shilpa Medicare has announced that its wholly owned subsidiary, Shilpa Pharma Lifesciences, has successfully completed a U.S. Food and Drug Administration (FDA) inspection at its Unit-2 API manufacturing facility in Raichur, India, with no Form 483 observations issued. The audit, which took place from March 10 to March 14, marks the second consecutive clean inspection for the site.

Located on a 22-acre plot, Unit-2 is the company’s second and largest API manufacturing site and has been operatio...]]&gt;</description><pubDate>2025-04-09</pubDate><author>Ep News Bureau</author><media:content url="https://cdn.expresspharma.in/wp-content/uploads/2020/06/13205606/stamp-e1726045571234.jpg" medium="image" /></item></channel></rss>